Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lotz

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Mabs|March 5, 2024
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsSophie Tourdot, Daniel Baltrunkonis, Sofie Denies, et al.
Mabs|November 17, 2022
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic miceJerome Egli, Stefan Heiler, Felix Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2005
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trialJ-P Lotz, B Bui, F Gomez, et al.
Journal of Gynecology Obstetrics and Human Reproduction|December 1, 2023
Impact of molecular genotyping on the diagnosis and treatment of human chorionic gonadotropin-producing tumorsM Peyle, M Massoud, S Patrier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
The AAPS Journal|May 13, 2022
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity PlatformGregor P Lotz, Karin Benstein, Karien Bloem, et al.
British Journal of Cancer|October 9, 1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre studyC Chabannon, K Cornetta, J P Lotz, et al.
Bone Marrow Transplantation|May 29, 1998
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registryP Moreau, J Fleury, P Brice, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2014
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II studyF Selle, S Wittnebel, P Biron, et al.
Nature Chemical Biology|November 1, 2011
Identifying polyglutamine protein species in situ that best predict neurodegenerationJason Miller, Montserrat Arrasate, Elizabeth Brooks, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Mabs|March 5, 2024
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsSophie Tourdot, Daniel Baltrunkonis, Sofie Denies, et al.
Mabs|November 17, 2022
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic miceJerome Egli, Stefan Heiler, Felix Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2005
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trialJ-P Lotz, B Bui, F Gomez, et al.
Journal of Gynecology Obstetrics and Human Reproduction|December 1, 2023
Impact of molecular genotyping on the diagnosis and treatment of human chorionic gonadotropin-producing tumorsM Peyle, M Massoud, S Patrier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
The AAPS Journal|May 13, 2022
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity PlatformGregor P Lotz, Karin Benstein, Karien Bloem, et al.
British Journal of Cancer|October 9, 1998
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre studyC Chabannon, K Cornetta, J P Lotz, et al.
Bone Marrow Transplantation|May 29, 1998
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registryP Moreau, J Fleury, P Brice, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2014
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II studyF Selle, S Wittnebel, P Biron, et al.
Nature Chemical Biology|November 1, 2011
Identifying polyglutamine protein species in situ that best predict neurodegenerationJason Miller, Montserrat Arrasate, Elizabeth Brooks, et al.
Pageof 21